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Available online 4 April 2013AbstractIntroduction: Standardized methods of reporting complications after radical cystectomy (RC) and urinary diversions (UD) are necessary to
evaluate the morbidity associated with this operation to evaluate the modified Clavien classification system (CCS) in grading perioperative
complications of RC and UD in a real life cohort of patients with bladder cancer.
Materials and methods: A consecutive series of patients treated with RC and UD from April 2011 to March 2012 at 19 centers in Italy was
evaluated. Complications were recorded according to the modified CCS. Results were presented as complication rates per grade. Univariate
and binary logistic regression analysis were used for statistical analysis.
Results: Results and limitations: 467 patients were enrolled. Median age was 70 years (range 35e89). UD consisted in orthotopic neoblad-
der in 112 patients, ileal conduit in 217 patients and cutaneous ureterostomy in 138 patients. 415 complications were observed in 302 pa-
tients and were classified as Clavien type I (109 patients) or II (220 patients); Clavien type IIIa (45 patients), IIIb (22 patients); IV (11
patients) and V (8 patients). Patients with cutaneous ureterostomy presented a lower rate (8%) of CCS type IIIa ( p ¼ 0.03). A longer
operative time was an independent risk factor of CCS III (OR: 1.005; CI: 1.002e1.007 per minute; p ¼ 0.0001).* Corresponding author. Tel.: þ39 0633777716; fax: þ39 0633775428.
E-mail address: cosimodenunzio@virgilio.it (C. De Nunzio).
0748-7983/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
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793C. De Nunzio et al. / EJSO 39 (2013) 792e798Conclusions: In our study, RC is associated with a significant morbidity (65%) and a reduced mortality (1.7%) when compared to previous
experiences. The modified CCS represents an easily applicable tool to classify the complications of RC and UD in a more objective and
detailed way.
 2013 Elsevier Ltd. All rights reserved.
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Bladder cancer represents the 7th most common cancer in
men and the 17th in women.1,2 Since the early 1960s, radical
cystectomy and pelvic lymphadenectomy have been consid-
ered the standard management of muscle invasive bladder
cancer (MIBC) and a valid option for selected patients with
high grade nonmuscle invasive bladder cancer (NMIBC).3e6
Notwithstanding improvements in surgical technique, tech-
nology and preoperative care have reduced the perioperative
complication rate and even lowered the perioperativemortal-
ity rate from nearly 20% to less than 2%; radical cystectomy
(RC) is still associated with a significant perioperative and
long term morbidity ranging from 19% to 64% according
to the different series.7 However, complications associated
with RC have been frequently classified as minor or major
based on different definitions, which made an effective com-
parison of the different series impossible and highlight the
fact that standardized methods for reporting data on surgical
complications or morbidity after RC are urgently needed.7
The Clavien classification system (CCS) for surgical compli-
cations was originally developed in the 1990s and thereafter
modified and validated6,7; nowadays it will probably repre-
sent the upcoming standard for both reporting complications
and quality standard.8e10 Few retrospective studies, mostly
in tertiary referral centers with a long enrollment period
and focusing exclusively on ileal urinary diversions, exam-
ined complications using a CCS and have reported rates be-
tween 48% and 74%.11e13
The aim of our study was to prospectively evaluate, in
a one-year multicenter Italian cohort of patients, the appli-
cability of the modified CCS in grading perioperative com-
plications of RC and urinary diversions (UDs) in patients
with bladder urothelial carcinoma.Materials and methodsPatients and samplesA consecutive series of patients treated with open RC,
lymphadenectomy and UD from April 2011 to March 2012
at 19 centers in Italy were evaluated for complications occur-
ring up to the end of the third postoperative month. The indi-
cations for surgery included muscle invasive urothelial
carcinoma, selected patients with high grade NMIBC, BCGresistant carcinoma in situ and NMIBC that cannot be man-
aged with transurethral resection. No exclusion criteria
were considered. Age, sex, co-morbidities, smoking history,
anthropometric parameters including body mass index
(BMI), American Society of Anaesthesiologists (ASA) score,
history of previous medical and surgical treatments and de-
tails of surgery were recorded from all patients. Clinical
and pathological stages were evaluated for all the patients ac-
cording to the TNM 2010 staging system.14 Antiaggregants
and anticoagulant drugs were stopped at least 1 week before
the operation. Daily administration of subcutaneous low-
molecular weight heparin was initiated 12 h before surgery
and maintained for at least 4 weeks postoperatively. Polyeth-
ylene glycol solution was routinely administered the after-
noon before surgery for bowel preparation. An elastic
compressive stocking was used as mechanical prophylaxis
for deep vein thrombosis (DVT) and third-generation cepha-
losporin was administered intravenously when anesthesia
was initiated and maintained for 5 days postoperatively.Surgical techniqueAll operations were performed by an expert qualified
uro-oncology consultant in each center.
RC was performed according to the procedure suggested
by the International Consultation on Bladder Cancer.15
Lymph node dissection extension included the removal of
all lymphatic tissues around the common iliac, external il-
iac, internal iliac arteries and from the obturator region bi-
laterally and the presacral region.15,16 UD consisted of
cutaneous ureterostomy according to the Glenn tech-
nique17,18; ileal conduit according to the Bricker or Wallace
technique11,19 and ileal orthotopic neobladder according to
the Studer or Camey or Padua techniques.16,19,20
All uretero-intestinal and uretero-cutaneous anastomosis
were stented intraoperatively regardless of the form of UDs
for at least 12 days. Patients with orthotopic neobladders
underwent a contrast cystogram 3 weeks postoperatively
and the urethral catheter was removed provided no signifi-
cant leakage was observed.Complications evaluationAll complications within 90 days of surgery were pro-
spectively recorded and classified according to the modified
Table 1
Descriptive preoperative data of 467 patients undergoing radical
cystectomy.
Age (yrs) 70 (35e89)
Gender Male: 379 patients
Female: 88 patients
Smoker 246 patients
794 C. De Nunzio et al. / EJSO 39 (2013) 792e798CCS8 which stratifies perioperative complications into five
grades and focuses mainly on the therapeutic consequences
of a complication, emphasizing the level of intervention re-
quired to managed it.21 Likewise, perioperative mortality
was defined as death from any cause within 90 days of
surgery.Anticoagulant treatment 140 patients
Diabetes mellitus 88 patientsStatistical analysis
Hypertension 278 patients
Ischemic heart disease 93 patients
BMI (kg/m2) 25 (18e46)
Hemoglobin level (g/dl) 13 (9e17)
Chronic renal insufficiency (GFR < 59 ml/min) 35 patients
Hydronephrosis (%) 98 patients
ASA score
I 49 patients
II 195 patients
III 195 patients
IV 28 patients
Tumor size (cm) 4 (1e12)
Tumor lesions (number#) 1 (1e15)
*Data as median (range).
Table 2
Complications of radical cystectomy classified according to the modified
Clavien system.
Clavien classification Complications
Grade 1 109
Ileus paralytic 25
Infections 31
Transient elevation of creatinine 16Statistical analysis was performed using the S-PSS 12.0
software (Chicago, USA). Differences between groups of
patients in medians for quantitative variables and differ-
ences in distributions for categorical variables were tested
with the Kruskal Wallis one way analysis of variance and
chi-square test, respectively. Using multiple logistic regres-
sion with the enter method, the significant statistical vari-
ables as assessed in the univariate analysis were entered
and investigated as predictors of severe complications
(CCS III) vs. no or low-grade (CCS II) complications.
The variables considered for entry into the model included
age, sex (categorical), presence of hydronephrosis (categor-
ical), ASA score (categorical variable), operative time,
pathological stage (categorical) and type of urinary diver-
sion (categorical). An alpha value of 5% was considered
as the threshold for significance. Data are presented as me-
dian (range). Odds ratios and 95% CI’s were calculated for
the parameters in each group using no and low grade com-
plications as a reference group.
Results
Metabolic imbalance 10
Transient reduction of Hb 12
Lymph discharge 6
Patient characteristicsTransitory ischemic attack 3
Dyspnea 6
Grade 2 220
Blood transfusions 182
Infections 20
Small bowel obstruction 17
Deep venous trombosis 1
Grade 3a 45
Urinary leakage 16
Wound or pelvic Infections 8
Hydronephrosis 5
Small bowel obstruction 8
Lymphocele 3
Pneumotorax 2
Pelvic hematoma 3
Grade 3b 22
Urinary leakage 6
Wound infections 6
Small bowel obstruction or leakage 9
Pelvic hematoma 1
Grade 4a 9
Myocardial infarction 4467 patients were prospectively and consecutively en-
rolled. Descriptive data of the cohort are summarized in
Table 1.
None of the patients received neoadjuvant chemother-
apy. All patients underwent RC and lymph nodes dissec-
tion. UD consisted in orthotopic neobladder in 113
patients, ileal conduit in 217 patients and bilateral cutane-
ous ureterostomy in 138 patients. Median operative time
was 270 min (95e720); median estimated blood loss was
1290 cc (500e2000); median time to fluid intake was 5
days (2e28). Median time to stool passage was 6 days
(3e28). Median length of stay was 13 (6e119) days. Path-
ological stage was T0 in 28 patients; T1 in 36 patients (4
G1; 7G2 and 25 G3); T2 in 103 patients (44 G2 and 59
G3); T3 in 165 (35.5%) patients (55 G2 and 110 G3); T4
in 99 patients (38 G2 and 61 G3) and CIS in 36 patients
(7.8%). Overall 141 patients presented a pathological N
stage 1.Lung failure 4
Kidney failure 1
Grade 4b 2Clavien classification system evaluationUrosepsis 2
Grade 5 8
Overall 415
A total of 415 complications were recorded in 302 pa-
tients with an incidence of perioperative complications of
Table 3
Analysis of the complications classified according to the CCS and perio-
perative patient’s characteristics.
No complications Complications p
Patients 165 302
Age (yrs) 71 (65e76) 70 (35e89) 0.588
Female 23 64 0.054
BMI (kg/m2) 25.5 (23e34) 25 (22e46) 0.616
Hemoglobin level (g/dl) 13 (9e17) 12 (9e16) 0.254
Hydronephrosis 28 70 0.07
Diabetes mellitus 26 62 0.218
Hypertension 98 180 0.521
Ischemic heart disease 34 59 0.73
Chronic renal failure 27 8 0.075
ASA score
I 15 34 0.232
II 79 116
III 65 130
IV 6 22
Tumor size (cm) 4 (1e12) 4 (1e10) 0.347
2010 TNM pathological T stage
T1 or less 17 47 0.442
T2 45 58
T3eT4 92 172
CIS 11 25
2010 TNM pathological N0 114 212 0.441
Operative time (min) 256 (95e640) 272 (95e720) 0.189
Length of stay (days) 12 (6e40) 14 (6e119) 0.534
Data presented as median (range).
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ien type I (109 complications) or II (220 complications).
Higher grade complications were observed: 45 Clavien
type IIIa, 22 Clavien type IIIb, 11 Clavien type IV and 8Table 4
Patient’s characteristics according to the different type of urinary diversions.
Ureterocutanesostomy
Patients 138
Age (yrs) 75.5 (35e89)
BMI (kg/m2) 24.6 (23e28)
Preoperative hemoglobin level (g/dl) 11.6 (9e13)
Hydronephrosis (%) 42
Diabetes mellitus 29
Hypertension 100
Ischemic heart disease 40
Chronic renal failure 20
ASA score
I 9
II 46
III 67
IV 16
Tumor size (cm) 5 (1e10)
2010 TNM path. T stage
T1 or less 14
T2 32
T3eT4 88
CIS 4
2010 TNM path. N0 84
Operative time (min) 189 (95e600)
Estimated blood loss (cc) 1340 (500e2000)
Length of stay (days) 12 (6e119)
Data presented as median (range).Clavien type V. Overall, 8 patients died and out of them
three during the first postoperative month.
Overall, 182 patients required blood transfusion for peri-
operative bleeding. Most of the complications (311 compli-
cations) occurred during the initial hospitalization, and the
remaining 104 following discharge. No significant associa-
tion between clinical, pathological variables and the occur-
rence of any type of complications was observed (Table 3).
Patients with ureterocutaneostomy presented a higher rate
of co-morbidity (hypertension, ischemic heart diseases,
chronic renal failure), hydronephrosis and as a consequence
a higher ASA score when compared to the ileal conduit or to
the orthotopic neobladder (Table 4). Advanced disease (pT3-
4) was also more frequent in patients who received a cutane-
ous ureterostomy (Table 4). Ileal conduit and orthotopic
neobladder required a significantly longer operative time
when compared to cutaneous ureterostomy ( p ¼ 0.001).
No significant differences ( p ¼ 0.991) were observed
for the overall rate of complications in the three different
UDs (112 complications in 138 patients for cutaneous ure-
terostomy; 201 complications in 217 patients for the ileal
conduit and 102 complications in 112 patients for the ortho-
topic neobladder).High grade (CCS IIIa) complications evaluationOverall, 65 patients experienced high grade CCS (IIIa)
complications and 67 reinterventions (general or local anes-
thesia) were required: 14 for wound or pelvic infections; 22
for urinary anastomosis leakage; 17 for ileal perforation orIleal conduit Orthotopic neobladder p
217 113
71 (47e86) 63 (36e77) 0.001
26.4 (22e46) 25 (27e40) 0.237
12.7 (9e17) 13.2 (10e17) 0.008
42 14 0.002
42 17 0.485
129 49 0.001
41 12 0.001
12 3 0.001
0.001
23 17
89 60
95 33
10 2
4 (1e12) 4 (1e7) 0.191
0.008
34 16
39 32
126 50
18 14
152 80 0.064
300 (95e720) 290 (105e720) 0.001
1600 (500e1713) 1140 (1100/1365) 0.644
13 (6e60) 14 (6e35) 0.036
Table 5
Patient’s characteristics according to the different grade of complications.
No complications or
CCS II
CCS IIIa p
Patients 402 65
Age (yrs) 71 (35e85) 70.3 (10); 70
(43e89)
0.279
Female/male ratio 77 10 0.297
BMI (kg/m2) 25 (22e40) 24 (18e46) 0.724
Hemoglobin level (g/dl) 12.2 (9e17) 13 (9e16) 0.639
Hydronephrosis (%) 86 12 0.362
Diabetes mellitus 70 18 0.06
Hypertension 233 45 0.102
Ischemic heart disease 80 13 0.550
Chronic renal failure 27 8 0.096
ASA score 0.259
I 40 9
II 173 22
III 163 32
IV 26 2
Tumor size (cm) 4 (1e12) 4.5 (1e10) 0.697
2010 TNM pathological T
stage
0.761
T1 or less 55 9
T2 87 16
T3eT4 227 37
CIS 33 3
2010 TNM pathological
N0
121 20 0.559
Operative time (min) 260 (95e640) 343 (108e720) 0.001
Length of stay (days) 12 (6e50) 20 (6e119) 0.001
*Data presented as median (range).
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pneumotorax and 3 for lymphocele. In patients with CCS
IIIa a longer operative time and length of stay were ob-
served when compared to patients with no or low grade
(CCS II) complications (Table 5). Patients who received
a cutaneous ureterostomy presented a significantly
( p ¼ 0.03) lower rate of high grade CCS  3 (11 compli-
cations in 138 patients) when compared to ileal conduit (35
complications in 217 patients) and orthotopic neobladder
(19 complications in 112 patients). On multivariate analy-
sis, a longer operative time was confirmed to be a signifi-
cantly independent risk factor of high grade (CCS IIIa)
complications (OR: 1.005; CI: 1.002e1.007 per minute;
p ¼ 0.0001), despite the type of UD.
DiscussionRadical cystectomy morbidity and mortality rateRadical cystectomy and pelvic lymphadenectomy is the
standard treatment for patients with muscle invasive or
high risk NMIBC although it is associated with a high
risk of severe complications.11,22 In our prospective multi-
center group of patients enrolled for one year and treated
with RC and three different types of UD, we observed
a low one month (0.63%) and three months (1.7%)mortality rate associated with an elevated (65%) morbidity
which was higher when compared to the data reported by
Novara et al.11 and by Shabsigh et al.12 However, our
group of patients were older (median 70 years vs. 65 and
68 respectively) and with a higher prevalence of co-
morbidities as diabetes or arterial hypertension. Further-
more, they11,12 retrospectively evaluated only patients
treated in a single tertiary referral, enrolled over a long
range of time (5e10 years) using exclusively an ileal UD
(ileal conduit, continent pouch or orthotopic neoblad-
der).11,12 Our experience included patients from 19 differ-
ent teaching and non-teaching hospitals and better reflects
the real life activity in Italy. In particular, cutaneous ureter-
ostomy was the selected UD in about 25% of our patients.
Although cutaneous ureterostomy is performed worldwide
in about 2/10% of patients treated with RC,23 it is still
a common procedure in Italy and in a real life setting it
could be indicated in patients with advanced bladder can-
cer and higher co-morbidities as observed in our series.
In this group of patients we particularly observed, together
with advanced bladder cancer, a higher incidence of hydro-
nephrosis and co-morbidities when compared to patients
receiving an ileal UD (Table 4). Most of these procedures
were performed without any curative intent or to improve
patients’ survival but only as a palliative procedure to
avoid future worsening of the patients’ quality of life
that may derive from hematuria with clot formation, uri-
nary retention, pain from infiltration of the pelvic nerves
and renal failure.
The most common complication categories were hema-
tological (198 complications), gastrointestinal (57 compli-
cations), infectious (51 complications), wound related (16
complications) and genito-urinary (30 complications). Al-
though 415 complications were observed in 302 patients,
most of them (329 complications) were considered not se-
vere (CCS II) according to the CCS. In this group of pa-
tients the most common complication was blood
transfusion which was necessary in 182 patients during
the perioperative observation time with an average esti-
mated blood loss of 1200 ml which is in the same range re-
ported by other groups (560e3000 ml).24,25 The non
significant differences in terms of estimated blood loss
were observed among the three different UDs which under-
line how this type of complication can be attributable to the
RC procedure independently from the UD procedure.Radical cystectomy and high grade (CCS IIIa)
complicationsIn our analysis, a small number of patients (65 patients)
experienced high grade complications (CCS 3a) and most
of them were related to small bowel obstruction (17 com-
plications) or anastomosis urinary leakage and hydroneph-
rosis (27 complications). We confirmed in our series how
CCS IIIa complications are mostly related to the UD
procedure and particularly to the ileal resection and
797C. De Nunzio et al. / EJSO 39 (2013) 792e798anastomosis or to the ureteric and urethra anastomosis. The
relation of CCS IIIa complications with ileal UD can also
explain the similar trend of the high rate of these complica-
tions observed in all the studies on robotic, open or laparo-
scopic RC where the ileal UD is always performed through
a midline incision11,21,25,26 independently from the open,
laparoscopic or robotic approach.
Furthermore, this hypothesis is confirmed in our series
by the group of patients with cutaneous ureterostomy where
we observed a lower rate (8%) of CCS IIIa complications
when compared to the ileal conduit (16%) and the ileal or-
thotopic neobladder (17%). Although we acknowledge that
ileal conduit and orthotopic neobladder should be consid-
ered as the standard UD in patients treated with RC, in
our experience, in patients with significant co-morbidities,
cutaneous ureterostomy could be proposed and discussed
in selected patients in order to reduce the morbidity associ-
ated with ileal UD.
Multivariate analysis showed that operative time was
a statistically significant independent predictor of CCS
IIIa despite the type of UD. Although our results could
be in relation to the reduced statistical power associated
with the smaller number of patients who experienced
CCS IIIa complications (65 patients), it could reflect
that a longer operative time is required in patients with
technically demanding procedures in relation to the pa-
tient’s habit, tumor stage, previous surgery, or intraopera-
tive complications; it can also reflect particular
anesthesiological needs and can induce metabolic imbal-
ance, resulting in a higher rate of high grade postoperative
complications. The average length of stay after a RC ranges
between 7 and 34 days according to the different centers,
with significant differences between Europe (longer length
of stay) and American (shorter length of stay) hospi-
tals.11,12 In our experience the median length of stay was
13 days (range 6e119) and it was significantly longer in
patients with high grade complications. However, com-
pared to other series our median length of stay was shorter
probably in relation to the different types of UDs included
in our series. In particular, patients with cutaneous ureteros-
tomy presented significant shorter hospitals stay when com-
pared to ileal UDs.Study limitationsDespite the fact that to our knowledge this study repre-
sents the largest multi-institution analysis of RC and UDs
using the CCS, we must acknowledge some limitations.
The relationship between hospital volume and RC outcome
in terms of morbidity and mortality is well established.21 In
our series 19 different centers from teaching and non-teach-
ing hospitals were involved in this project and the results
obtained in our experience could not be referred or transfer-
able to high volume cancer centers. Even though some au-
thors21 took into consideration 50 procedures per year as
the desirable cystectomy rate in order to minimize thepossible complications, the International Consultation on
Bladder cancer has recently proposed an annual rate of
10 RC procedures per hospital as an adequate rate.15 In
our series, all the centers involved reached this standard
(median 21 RC per center, range 13e40). Another possible
limitation of our study is related to the small sample size
when compared to other larger American series.12,21 How-
ever, we decided to reduce the enrollment period to one
year and consequently the sample size in order to have
a precise and real life picture of these procedures and to
minimize the possible influence of the surgical and techno-
logical progress which has been particularly evident year
after year in the last decades. Finally, although ileal conduit
and orthotopic neobladder are considered the standard
UDs23 in our series, about 25% of the patients received a cu-
taneous ureterostomy which influenced our results and re-
duced the possibility of comparing our entire group of
patients with the available evidence. However, we present
a real life experience in our study where this type of UD
is still a frequent option. Furthermore, including the pa-
tients in our series, we better highlighted and demonstrated
the direct relationship between high grade complications
and ileal UD.
Conclusions
In our study we confirmed, in one year of a real life co-
hort of patients, that the CCS is a feasible method to eval-
uate early morbidity after RC and UDs. Although most of
the complications were minor, 12% of the patients experi-
enced high grade complications and most of them were ob-
served in patients who received ileal UDs (orthotopic
neobladder or ileal conduit). Although mortality rate has
dropped significantly over the last decades, perioperative
complications remain common.Acknowledgment statement
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